

A case of cerebral vasculitis due to neurobartonellosis

Meryim Poursheykhi, MD,* Farhan Mithani, BS,* Tanu Garg, MD,* Christian Cajavilca, MD, Siraya Jajjakul, MD, Steve Fung, MD, Richard Klucznik, MD, and Rajan Gadhia, MD

Neurol Neuroimmunol Neuroinflamm 2020;7:e791. doi:10.1212/NXI.0000000000000791

Correspondence

Dr. Poursheykhi
mpoursheykhi@
houstonmethodist.org

We report a case of a 60-year-old right-handed woman with hypertension, hyperlipidemia, and hypothyroidism who presented with a three-week history of recurrent thunderclap headaches accompanied by photophobia, phonophobia, nausea, and vomiting. She reported one brief episode of slurred speech, expressive aphasia, right facial droop, and right hemiparesis suggestive of a TIA. Family history was remarkable for primary angiitis of the CNS (PACNS) in the mother. Neurologic examination was unremarkable. CT of the head was negative; CT angiography (CTA) of the head and neck suggested fibromuscular dysplasia in bilateral cervical internal carotid arteries and distal right vertebral artery. MRI of the brain showed no correlating abnormalities. A digital subtraction angiography (DSA) revealed multivessel intracranial medium and large vessel narrowing and fusiform dilatations, suggestive of reversible cerebral vasoconstriction syndrome (RCVS) vs vasculitis. Subsequent MR intracranial vessel wall imaging (IVWI) showed multifocal concentric vessel wall thickening and enhancement consistent with vasculitis (figure). Transcranial Doppler showed no evidence of elevated intracranial velocities. CSF studies were unremarkable with an opening pressure of 10 cm H₂O, 2 white blood cells (normal 0–5/mm³), 2 red blood cells (normal 0–1/mm³), 58 mg/dL glucose (normal 40–70, serum glucose 87), 41 mg/dL protein (normal 15–45), normal Q-albumin ratio, normal IgG synthetic rate, and IgG index. Serum inflammatory and infectious studies had been negative thus far. Empiric high-dose IV steroids lead to complete symptom resolution. Final infectious workup revealed strongly positive serum *Bartonella* IgM titer of 1:256 and negative IgG, consistent with her reported cat exposure. She was started on an outpatient two-week course of doxycycline, rifampin, and oral steroids. Four weeks later, repeat vessel wall MRI and *Bartonella* serologies (IgM titer 1:80) showed improvement.

Discussion

We present an individual with symptoms initially concerning for RCVS vs vasculitis who was subsequently found to have secondary CNS vasculitis due to cat-scratch disease (CSD). To our knowledge, this is the first adult case of *Bartonella henselae*-associated CNS vasculitis, particularly without encephalopathy as the presenting symptom.

CSD typically presents with self-limited regional lymphadenopathy and fever.¹ Neurologic complications are rare, occurring in 2% of cases with encephalopathy as the most common manifestation.² Neuroretinitis, seizures, coma, myelopathies, and cranial and peripheral nerve involvement have also been reported. CNS vasculitis associated with CSD, however, has only been reported in 2 pediatric cases which presented with strokes.^{3,4}

Diagnostically, identifying primary and secondary CNS vasculitis can be challenging both clinically and radiographically. No specific studies in serum or CSF are available for the diagnosis of CNS


*These authors contributed equally to the manuscript.

From the Department of Neurology (M.P., T.G., R.G.), Department of Infectious Diseases (S.J.), Department of Neuroradiology (S.F.), and Department of Interventional Neuroradiology (R.K.), Houston Methodist Hospital, TX; Texas A&M Health Science Center College of Medicine (F.M.), Bryan; and Department of Interventional Neurology (C.C.), Texas Stroke Institute, Plano.

The Article Processing Charge was funded by the authors.

Go to [Neurology.org/NN](https://www.neurology.org/NN) for full disclosures. Funding information is provided at the end of the article.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.



(A) Angiogram of the left internal carotid artery showing multifocal narrowing and fusiform dilations (arrows) pretreatment. (B) Intracranial vessel wall MRI showing multifocal concentric vessel wall thickening and enhancement (arrows) pretreatment. (C) Intracranial vessel wall MRI showing reduction in vessel wall enhancement (arrows) posttreatment. (D) Magnetic resonance angiography (MRA) head showing multifocal stenoses (arrows) pretreatment. (E) MRA head showing improvement of stenoses (arrows) posttreatment.

vasculitis. As in neurobartonellosis, CSF may be unremarkable or reveal nonspecific mild lymphocytic pleocytosis. Cerebral vasculopathies can present with similar luminal patterns, and therefore, imaging modalities such as DSA, magnetic resonance angiography (MRA), and CTA provide nonspecific results leading to difficulties identifying and differentiating between common etiologies of intracranial disease including vasospasm, atherosclerosis, and inflammation. Although DSA remains the gold standard for vessel imaging, it is an invasive study that provides information limited to the vessel lumen. Conversely, IVWI allows direct visualization of the vessel wall by subtracting the signal of blood in the vessel lumen and has shown to improve diagnostic specificity.⁵ In CNS vasculitis, IVWI shows multifocal concentric vessel wall enhancement and thickening as seen in our patient. In RCVS, vessel wall thickening may be present but with minimal or no enhancement.⁵

At this time, there is no clear evidence-based treatment regimen or duration for neurologic manifestations of CSD

including CNS vasculitis.¹ We recommend concomitant treatment of the infection with antibiotics and secondary vasculitis with high-dose steroids. Our patient received a 2-week combination of doxycycline 100 mg and rifampin 300 mg twice daily per current expert opinion.⁶ In addition, we initiated 5 days of high-dose IV steroids, followed by a 1-week oral steroid taper. To avoid recurrent invasive testing, we repeated IVWI 4 weeks later for treatment monitoring and found significant reduction in vessel wall enhancement (figure).

Our case reiterates the importance of ruling out rare causes of CNS vasculitis including assessing animal exposure before diagnosing PACNS. Detection of the etiology of vasculitis is essential to guide treatment and for prognostication. Non-invasive imaging such as an IVWI provides valuable diagnostic information and can be useful in assessing the treatment response over time by minimizing the need for repeat invasive DSA.

Acknowledgment

The authors thank Dr. Gadhia for his mentorship.

Study funding

No targeted funding reported.

Disclosure

M. Poursheykhi, F. Mithani, T. Garg, C. Cajavilca, S. Jaijakul, S. Fung, R. Klucznik, and R. Gadhia report no disclosures. Go to Neurology.org/NN for full disclosures.

Publication history

Received by *Neurology: Neuroimmunology & Neuroinflammation* April 19, 2020. Accepted in final form May 7, 2020.

Appendix Authors

Name	Location	Contribution
Meryim Poursheykhi, MD	Houston Methodist Hospital, TX	Conceptualized the study, conducted literature review, interpreted the data, and drafted and revised the manuscript for intellectual content
Farhan Mithani, BS	Texas A&M Health Science Center College of Medicine, Bryan	Conceptualized the study, conducted literature review, interpreted the data, and drafted and revised the manuscript for intellectual content
Tanu Garg, MD	Houston Methodist Hospital, TX	Conceptualized the study, conducted literature review, interpreted the data; drafted and revised the manuscript for intellectual content

Appendix (continued)

Name	Location	Contribution
Christian Cajavilca, MD	Texas Stroke Institute, Plano	Interpreted data and revised the manuscript for intellectual content
Siraya Jaijakul, MD	Houston Methodist Hospital, TX	Interpreted data and revised the manuscript for intellectual content
Steve Fung, MD	Houston Methodist Hospital, TX	Interpreted data and revised the manuscript for intellectual content
Richard Klucznik, MD	Houston Methodist Hospital, TX	Interpreted data and revised the manuscript for intellectual content
Rajan Gadhia, MD	Houston Methodist Hospital, TX	Interpreted data and revised the manuscript for intellectual content

References

1. Breitschwerdt E, Sontakke S, Hopkins S. Neurological manifestations of bartonellosis in immunocompetent patients: a composite of reports from 2005–2012. *J Neuro-parasitol* 2012;3:1–15.
2. Carithers HA, Margileth AM. Cat-scratch disease: acute encephalopathy and other neurologic manifestations. *Am J Dis Child* 1991;145:98–101.
3. Selby G, Walker GL. Cerebral arteritis in cat-scratch disease. *Neurology* 1979;29:1413–1418.
4. Balakrishnan N, Ericson M, Maggi R, Breitschwerdt EB. Vasculitis, cerebral infarction and persistent *Bartonella henselae* infection in a child. *Parasit Vectors* 2016;9:254.
5. Mossa-Basha M, Alexander M, Gaddikeri S, Yuan C, Gandhi D. Vessel wall imaging for intracranial vascular disease evaluation. *J Neurointerv Surg* 2016;8:1154–1159.
6. Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by *Bartonella* species. *Antimicrob Agents Chemother* 2004;48:1921–1933.